Oura Files for IPO as Smart Ring Maker Seeks $16 Billion Valuation

Oura has filed with the Securities and Exchange Commission to take the company public, formalizing a process that began with a confidential filing back in May. The numbers in the S-1 tell a growth story that would turn heads in any sector, let alone consumer hardware.

Revenue for the nine-month period ended June 30 hit $1.2 billion, up from $697 million in the same stretch a year earlier. That is roughly 72% growth, a pace few hardware companies sustain at this scale. Oura has previously disclosed $500 million in full-year 2024 revenue, near $1 billion in 2025, and guidance pointing to close to $2 billion for this year. If that guidance holds, the company will have quadrupled revenue in two years.

The ring itself sells for $350 to $400, a price point that positions it as a premium wellness device rather than a mass-market gadget. Oura says it has sold 3.6 million rings over the past year and now counts approximately 5 million paid subscribers, users who pay for the ongoing health-metrics service layered on top of the hardware. That subscription piece matters more than the unit sales figure. Hardware margins on a ring are one thing. Recurring software revenue at scale is another, and it is the software layer that Wall Street will price most aggressively.

Retention data backs up the subscription thesis. Oura reports an approximately 85% weighted-average 12-month membership retention rate, meaning most members who sign up in a given month are still paying a year later. For a $350 wearable with an attached subscription, that is a respectable number and one that supports a recurring-revenue narrative rather than a one-and-done hardware sale.

The Valuation Math

Bloomberg has reported that Oura is targeting a $16 billion valuation in the offering, with plans to raise $3 billion. That figure represents a substantial jump from the roughly $11 billion valuation the company carried as of October last year, less than a year ago. A move from $11 billion to $16 billion in under twelve months is aggressive, even against the backdrop of near-doubling revenue.

Run the simple math and the ask becomes clearer. At $16 billion against a projected $2 billion in 2026 revenue, Oura would be pricing itself at roughly 8 times forward sales. That is not an unreasonable multiple for a fast-growing subscription business, but it leaves little room for error. Any deceleration in ring sales, subscriber growth, or retention would compress that multiple quickly once public shareholders start applying quarterly scrutiny that private investors do not.

Oura's own S-1 language leans hard into total addressable market expansion. The filing states the company believes its opportunity extends beyond "traditional wearable use cases centered on activity and fitness tracking" and that its platform can serve "significantly larger populations" as it builds clinical evidence and deepens ties with health plans, employers, and care providers. That is a bet on becoming healthcare infrastructure rather than a fitness accessory, a much bigger vision and a much bigger risk if the clinical validation does not arrive on schedule.

The company also touts its data moat. Oura says it has assembled "one of the largest and highest-quality longitudinal biometric datasets in consumer health," tracking more than 50 health and wellness metrics across nearly 42 billion hours of physiological data. That dataset, the filing argues, powers machine-learning models that improve in accuracy and predictive capability as member histories deepen. It is a reasonable competitive argument. Data compounds, and a five-million-member base generating continuous biometric streams is not trivial to replicate.

Still, a data moat is only valuable if the underlying measurements are trustworthy, and that is precisely where Oura faces its most immediate headwind.

Key Risks

Oura is currently defending a proposed class action lawsuit accusing it of misleading consumers about the accuracy of its sleep tracking. The complaint alleges the rings cannot actually detect the physiological signals required to determine sleep stages, and instead rely on AI-generated estimates the suit describes as barely more reliable than a coin flip. That allegation, if it gains traction in discovery or draws regulatory attention, cuts directly against the "health intelligence platform" positioning Oura is selling to public investors. The litigation did not emerge from nowhere. It follows years of user complaints about the app rating sleep as optimal when users felt otherwise.

Oura has disputed the claims and said it will defend against them in the appropriate legal forum. That is a standard corporate response, but it does not eliminate the overhang. Litigation risk rarely derails an IPO outright, but it does give prospective shareholders a concrete reason to discount the growth narrative, particularly one built on the premise of expanding into clinical and employer-health partnerships where accuracy claims carry regulatory weight.

There is also the matter of category risk more broadly. Consumer hardware IPOs have a mixed track record, and wearables in particular compete against well-capitalized incumbents in fitness tracking, alongside a crowded field of health apps that do not require a $350 upfront purchase. Oura's retention numbers suggest it has built genuine habit and loyalty. Whether that loyalty survives a public earnings cycle, with the associated pressure to hit subscriber and revenue targets every ninety days, is a different question than whether it survives in private hands.

What Investors Should Watch

The offering will likely price on the strength of the revenue trajectory and the subscription retention story, both of which are genuinely strong on paper. Investors should watch three things once the roadshow begins: how the underwriters justify the jump from an $11 billion to $16 billion valuation given the sleep-tracking litigation, whether Oura discloses any settlement reserves or updated guidance tied to the lawsuit, and how the company frames its clinical and employer-partnership pipeline, since that expansion story is doing a lot of work to justify the multiple. Strong growth got Oura to the S-1. Credibility on accuracy claims will determine where the stock trades six months after the lockup expires.